InvestSMART

Mayne Pharma Group Limited (ASX: MYX) - Announcements

Current share price for MYX : $2.830 0.01 (0.35%)+

ASX company news and announcements for Mayne Pharma Group Limited (MYX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mayne Pharma Group Limited (MYX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mayne Pharma Group Limited (MYX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mayne Pharma Group Limited (MYX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$232 Retail Offer Booklet 30 Jun 2016 9:53AM $1.485 $2.830 risen by 90.57%
$232 Completion institutional entitlement offer and placement 30 Jun 2016 8:47AM $1.485 $2.830 risen by 90.57%
$232 Investor Presentation Acquisition of US generic portfolio 28 Jun 2016 8:57AM $1.485 $2.830 risen by 90.57%
$232 Section 708A notice 28 Jun 2016 8:57AM $1.485 $2.830 risen by 90.57%
$232 Appendix 3B 28 Jun 2016 8:56AM $1.485 $2.830 risen by 90.57%
$232 MYX announces acquisition of US generic product portfolio 28 Jun 2016 8:56AM $1.485 $2.830 risen by 90.57%
$232 Trading Halt 28 Jun 2016 8:46AM $1.485 $2.830 risen by 90.57%
$232 MYX receives first generic approval of Tikosyn capsules 7 Jun 2016 8:29AM $1.560 $2.830 risen by 81.41%
$232 Wilson HTM Rapid Insights Conference Presentation 2 Jun 2016 8:35AM $1.550 $2.830 risen by 82.58%
$232 Change in substantial holding from BTT 1 Jun 2016 4:40PM $1.550 $2.830 risen by 82.58%
$232 Mayne Pharma receives FDA approval for Doryx MPC tablets 23 May 2016 11:41AM $1.400 $2.830 risen by 102.14%
$232 Appendix 3B 22 Apr 2016 1:50PM $1.410 $2.830 risen by 100.71%
$232 Appendix 3B and lapse of employee options 5 Apr 2016 2:03PM $1.455 $2.830 risen by 94.50%
$232 Appendix 3B 7 Mar 2016 5:03PM $1.430 $2.830 risen by 97.90%
$232 Appendix 3B and ASIC Form 484 29 Feb 2016 6:47PM $1.240 $2.830 risen by 128.23%
$232 2016 Half Year Investor Presentation 26 Feb 2016 8:13AM $1.175 $2.830 risen by 140.85%
$232 2016 Half Year Media Release 26 Feb 2016 8:13AM $1.175 $2.830 risen by 140.85%
$232 Half Yearly Report and Accounts 26 Feb 2016 8:12AM $1.175 $2.830 risen by 140.85%
$232 Ceasing to be a substantial holder 26 Feb 2016 8:09AM $1.175 $2.830 risen by 140.85%
$232 Becoming a substantial holder 22 Feb 2016 8:15AM $1.240 $2.830 risen by 128.23%
$232 Appendix 3B 19 Jan 2016 12:32PM $1.200 $2.830 risen by 135.83%
$232 Appendix 3B 17 Dec 2015 5:31PM $1.400 $2.830 risen by 102.14%
$232 Change of Director's Interest Notice 14 Dec 2015 9:59AM $1.320 $2.830 risen by 114.39%
$232 Ceasing to be a substantial holder 14 Dec 2015 8:27AM $1.320 $2.830 risen by 114.39%
$232 Becoming a substantial holder 7 Dec 2015 8:21AM $1.360 $2.830 risen by 108.09%

801 - 825 of 902 results

Page 33 of 37

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.